CARY, N.C.,
Feb. 13,
2025 /PRNewswire/ -- Heron Therapeutics, Inc.
(Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage
biotechnology company, today announced that the Company will host a
conference call and live webcast on Thursday, February 27, 2025, at 8:00 a.m. ET to report fourth quarter and full
year 2024 financial results and discuss recent business
highlights.
The conference call can be accessed by phone by utilizing the
following registration link which will provide
participants with dial-in details. To avoid delays, we encourage
participants to dial into the conference call fifteen minutes ahead
of the scheduled start time. The conference call will also be
available via webcast under the Investor Relations section of
Heron's website at www.herontx.com. An archive of the
teleconference and webcast will also be made available on Heron's
website for 60 days following the call.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage
biotechnology company focused on improving the lives of patients by
developing and commercializing therapeutic innovations that improve
medical care. Our advanced science, patented technologies, and
innovative approach to drug discovery and development have allowed
us to create and commercialize a portfolio of products that aim to
advance the standard-of-care for acute care and oncology patients.
For more information, visit www.herontx.com.
Forward-looking Statements
This news release contains "forward-looking statements" as
defined by the Private Securities Litigation Reform Act of 1995.
Heron cautions readers that forward-looking statements are based on
management's expectations and assumptions as of the date of this
news release and are subject to certain risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, but are not limited to, risks and
uncertainties identified in the Company's filings with the
Securities and Exchange Commission. Forward-looking statements
reflect our analysis only on their stated date, and Heron takes no
obligation to update or revise these statements except as may be
required by law.
Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400
View original content to download
multimedia:https://www.prnewswire.com/news-releases/heron-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-thursday-february-27-2025-302376545.html
SOURCE Heron Therapeutics, Inc.
